NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

Technology Appraisal (Committee D) meeting minutes

**Minutes:** Confirmed

**Date:** Thursday 11 February 2021

**Location:** Via Zoom

# Committee members present

1. Professor Gary McVeigh [Chair] Present for all items
2. Dr Lindsay Smith [Vice Chair] Present for all items
3. Dr Carlo Berti Present for items 4 to 4.5.2
4. Martin Bradley Present for all items
5. Dr Matt Bradley Present for items 1 to 3.4.2 & 5 to 5.4.2
6. Professor Sofia Dias Present for all items
7. Professor Rachel Elliott Present for items 1 to 3.4.2 & 5 to 5.4.2
8. Dr David Foreman Present for items 4 to 4.5.2
9. Professor Paula Ghaneh Present for all items
10. Dr Rebecca Harmston Present for all items
11. Dr Robert Hodgson Present for items 1 to 4.5.2
12. Dr Bernard Khoo Present for all items
13. Dr Soo Fon Lim Present for all items
14. Dr Guy Makin Present for all items
15. Giles Monnickendam Present for all items
16. Malcolm Oswald Present for all items
17. Professor Chris Parker Present for all items
18. Baljit Singh Present for all items
19. Dr John Watkins Present for all items

# NICE staff present:

Helen Knight, Programme Director Present for items 4 to 4.3 & 4.5 to 4.5.2

Linda Landells, Associate Director Present for items 1 to 3.4.2 & 5 to 5.4.2

Jasdeep Hayre, Associate Director Present for items 4 to 4.5.2

David Thomson, Associate Director Present for items 4 to 4.5.2

Gavin Kenny, Project Manager Present for items 4 to 4.5.2

Kate Moore, Project Manager Present for items 1 to 3.4.2 & 5 to 5.4.2

Caron Jones, Technical Adviser Present for items 1 to 3.4.2

Chris Griffiths, Technical Adviser Present for items 4 to 4.5.2

Ella Livingstone, Technical Adviser Present for items 4 to 4.5.2

Jamie Elvidge, Technical Adviser Present for items 5 to 5.4.2

Luke Cowie, Technical Analyst Present for items 1 to 3.4.2

Adam Brooke, Technical Analyst Present for items 4 to 4.5.2

Steve Norton, Technical Analyst Present for items 4 to 4.5.2

Abitha Senthinathan, Technical Analyst Present for items 5 to 5.4.2

Maroulla Whiteley, Business Analyst, RIA Present for items 1 to 4.5.2

Ann Greenwood, Medical Editor Present for items 1 to 3.4.2

Ruth Melville, Medical Editor Present for items 1 to 3.4.2

Olivia Havercroft, Medical Editor Present for items 4 to 4.5.2

Sarah Bromley, Medical Editor Present for items 5 to 5.4.2

Emily Eaton Turner, Managed Access Team Present for items 1 to 3.4.2

Clare Hawksworth, Managed Access Team Present for items 5 to 5.4.2

Mandy Tonkinson, Public Involvement Adviser, PIP Present for items 1 to 3.3

Laura Marsden, Public Involvement Adviser, PIP Present for items 4 to 4.3

Maria Pitan, Project Manager, MIP Present for items 4 to 4.3

Catherine Pank, Assistant Project Manager, COT Present for items 1 to 3.4.2 & 5 to 5.4.2

Mira Patel, Coordinator, COT Present for items 4 to 4.5.2

Gemma Smith, Coordinator, COT Present for all items

Lucinda Evans, Coordinator, MIP Present for items 1 to 3.3 & 5 to 5.3

Victoria Hall, Coordinator, MIP Present for items 4 to 4.4.1

Ismahan Abdullah, Administrator, TA Present for items 1 to 3.4.2 & 5 to 5.4.2

Celia Mayers, Administrator, TA Present for items 4 to 4.5.2

Sophie McHugh, Administrator, COT Present for items 1 to 3.4.2 & 5 to 5.4.2

# External group representatives present:

Claire Rothery, NHS Centre for Reviews and Dissemination and Centre for Health Economics Present for items 1 to 3.3

Mark Corbett, NHS Centre for Reviews and Dissemination and Centre for Health Economics Present for items 1 to 3.3

Nigel Armstrong, Kleijnen Reviews Ltd Present for items 4 to 4.3

Robert Wolff, Kleijnen Reviews Ltd Present for items 4 to 4.3

Daniel Gallacher, Warwick Evidence Present for items 5 to 5.3

Hema Mistry, Warwick Evidence Present for items 5 to 5.3

# Professional experts present:

David Chandler, Chief executive, Psoriasis and Psoriatic Arthritis Alliance, Present for items 1 to 3.3

Dr Helena Marzo-Ortega, Consultant Rheumatologist and Honorary Clinical Associate Professor, Leeds Teaching Hospitals Trust & University of Leeds, Present for items 1 to 3.3

Helen McAteer, Chief Executive, Psoriasis Association, Present for items 1 to 3.3

Dr Jon Packham, Consultant Rheumatologist, Honorary Clinical Associate Professor in Rheumatology, Midlands Partnership NHS Foundation Trust / University of Nottingham Present for items 1 to 3.3

Professor Tim Kendall, Clinical Director for Mental Health, NHS England, Present for items 4 to 4.4.1

Professor Hamish McAllister, Professor of Affective Disorders, Newcastle University, Present for items 4 to 4.3

Esther Monaghan, Patient expert nominated by SANE, Present for items 4 to 4.3

Peter Pratt, Head of Medicines Strategy Mental Health, NHS England, Present for items 4 to 4.4.1

Peter Clark, CDF Clinical Lead, NHS England, Present for items 5 to 5.4.2

1. Introduction to the meeting
	1. The chair welcomed members of the committee and other attendees present to the meeting.
2. News and announcements
	1. None.
3. Appraisal of Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs [ID1658]
	1. Part 1 – Open session
		1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from Janssen
		2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Sofia Dias declared a non-financial interest as she works in the same department as the ERG for Guselkumab.
* It was agreed that her declaration would not prevent Sofia from participating in this section of the meeting.
* Professor Chris Parker declared financial interests as he has received honoraria from Janssen for a lecture on prostate radiotherapy in Feb 2020; an advisory board on apalutamide in March 2020; a lecture in November 2020 on PSA failure after treatment for prostate cancer.
* It was agreed that his declaration would not prevent Chris from participating I this section of the meeting.
* Dr John Packham declared direct financial and non-financial interest for the following reasons: his wife is the company director of a UK based pharmaceutical training company [predominantly focussing on ABPI code of practice]. Clients include all the top 20 pharmaceutical companies – but the training company has no special relationship or agreements with Janssen. He has no financial or managerial role in the company. He has received one payment from Lilly UK in 2019 for an educational session on identifying psoriatic arthritis in clinical care to the annual BSR conference and regarding the active rheumatology clinical trials unit within MPFT Trust – he has been PI for a Guselkumab in psoriatic arthritis study [COSMOS] with study activity within the past 12 months and has also acted as PI on 15 trials involving a wide variety of pharmaceutical companies and interventions during this period. No personal funding and no pharmaceutical activity other than acting as PI.
* It was agreed that his declaration would not prevent John from providing expert advice to the committee.
* Helen McAteer declared a financial interest as she is the Chief Executive of the Psoriasis Association who have declared relevant funding received from pharmaceutical companies in the last 12 months from Abbvie, Almirral, Amgen, Celgene, Dermal Laboratories, Eli Lilly, Janssen, LEO Pharma, UCB, and T & R Derma.
* It was agreed that her declaration would not prevent Helen from providing expert advice to the committee.
* Dr Helena Marzo-Ortega declared a financial interest as she has received research grants from Janssen and Novartis and received Speaker/Consultancy fees/honoraria from Celgene, Janssen, Eli-Lilly, Novartis, Pfizer, Takeda.
* It was agreed that her declaration would not prevent Helena from providing expert advice to the committee.
* No further conflicts of interest were declared for this item.
	1. The Chair introduced the lead team who gave presentations on the clinical effectiveness and cost effectiveness of the treatment
	2. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
	3. Part 2 – Closed session [company representatives, professional experts, external group representatives and members of the public were asked to leave the meeting]
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Document [FAD]. The committee decision was reached by consensus..
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Document [FAD] in line with their decisions.

1. Appraisal of Esketamine for treatment-resistant depression [ID1414]
	1. Part 1 – Open session
		1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from Janssen.
		2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Professor Hamish McAllister-Williams declared financial and non-financial interests as he is currently recruiting participants to two commercial studies funded by COMPASS pathways and LivaNova and over the last 3 years he has received fees for consultancy or giving talks at educational meetings from a number of pharmaceutical and neuromodulatory companies including: Lundbeck, Sunovian, LivaNova, Magstim, Syntropharma, Pfizer, P1vital and Janssen.
* It was agreed that his declaration would not prevent Hamish from providing expert advice to the committee.
* No further conflicts were declared for this appraisal.
	1. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document [ACD] received from consultees, commentators and through the NICE website
	2. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
	3. Part 2a – Closed session [external group representatives and members of the public were asked to leave the meeting].
		1. The committee discussed confidential information submitted for this item.
	4. Part 2b – Closed session [company representatives and professional experts, were asked to leave the meeting].
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Document [FAD] The committee decision was reached by consensus..
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Document [FAD] in line with their decisions.
1. Appraisal of Pembrolizumab for previously treated advanced or metastatic urothelial cancer - CDF review TA519 [ID1536]
	1. Part 1 – Open session
		1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from MSD
		2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* No conflicts of interest were declared for this appraisal.
	1. The Chair introduced the appeal panels outcome and presented the key themes.
	2. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
	3. Part 2 – Closed session [company representatives, professional experts, external group representatives and members of the public were asked to leave the meeting].
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Document [FAD] The committee decision was reached by consensus..
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Document [FAD] in line with their decisions.
1. Date of the next meeting

The next meeting of the Technology Appraisal (Committee D) will be held on Thursday 11 March 2021 and will start promptly at 09.30am.